Cite
HARVARD Citation
Gaudinski, M. et al. (2019). Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 393 (10174), pp. 889-898. [Online].